Literature DB >> 29606698

An Education and Field Experience Program to Increase Detection of Human Immunodeficiency Virus and Hepatitis C Virus.

Risha Irvin, Ayesha McAdams-Mahmoud, Jordan J White, Zackiya Grant, Oluwaseun Falade-Nwulia, Susan G Sherman, Chris Beyrer, Mark S Sulkowski, David L Thomas, Shruti H Mehta, Richard E Chaisson.   

Abstract

BACKGROUND: Baltimore is an urban center that has been highly impacted by human immunodeficiency virus (HIV) and hepatitis C virus (HCV); however, many individuals are unaware of their HIV and/or HCV status. In 2013, the Johns Hopkins Center for AIDS Research (CFAR) developed Generation Tomorrow, an HIV and HCV education, testing, and counseling program with community input and collaboration.
OBJECTIVES: The aims of Generation Tomorrow are to increase HIV and HCV awareness and detection in Baltimore and engage the next generation of health professionals (students) and community members (peers) in HIV and HCV outreach services.
METHODS: The Generation Tomorrow educational component includes formal HIV and HCV testing and counselling training, and a lecture series for students and peers. The participants then engage in field assignments and outreach events with Johns Hopkins associated programs or community-based organizations.
RESULTS: Generation Tomorrow trained 71 students and peers in three cohorts, 70% of whom reported that they planned to stay in HIV- and/or HCV-related work. From October 2014 to May 2015, which represents the first year that Generation Tomorrow ran with the full academic calendar, Generation Tomorrow students and peers worked with partner organizations to conduct 1,104 HIV rapid antibody tests and found 19 individuals (1.72%) to be HIV positive. Additionally, 778 HCV rapid antibody tests were conducted and 175 individuals (22.5%) were HCV antibody positive.
CONCLUSIONS: Generation Tomorrow has been successful in engaging students and community peers in HIV and HCV education, testing, and counseling, and has documented HIV and HCV positivity rates well above general community prevalence.

Entities:  

Mesh:

Year:  2018        PMID: 29606698      PMCID: PMC6428210          DOI: 10.1353/cpr.2018.0011

Source DB:  PubMed          Journal:  Prog Community Health Partnersh        ISSN: 1557-0541


  7 in total

1.  Changes in blood-borne infection risk among injection drug users.

Authors:  Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

2.  Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002.

Authors:  Joanne E Brady; Samuel R Friedman; Hannah L F Cooper; Peter L Flom; Barbara Tempalski; Karla Gostnell
Journal:  J Urban Health       Date:  2008-03-15       Impact factor: 3.671

3.  The HIV care cascade through time.

Authors:  Edward M Gardner; Benjamin Young
Journal:  Lancet Infect Dis       Date:  2013-09-27       Impact factor: 25.071

4.  Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008.

Authors:  Maxine M Denniston; R Monina Klevens; Geraldine M McQuillan; Ruth B Jiles
Journal:  Hepatology       Date:  2012-04-10       Impact factor: 17.425

5.  Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening.

Authors:  R Irvin; A McAdams-Mahmoud; D Hickman; J Wilson; W Fenwick; I Chen; N Irvin; O Falade-Nwulia; M Sulkowski; R Chaisson; D L Thomas; S H Mehta
Journal:  J Community Med Health Educ       Date:  2016-05-30

6.  Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases.

Authors:  D L Thomas; R O Cannon; C N Shapiro; E W Hook; M J Alter; T C Quinn
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

Review 7.  The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.

Authors:  Baligh R Yehia; Asher J Schranz; Craig A Umscheid; Vincent Lo Re
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

  7 in total
  1 in total

1.  Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland.

Authors:  Risha Irvin; Boatemaa Ntiri-Reid; Mary Kleinman; Tracy Agee; Jeffrey Hitt; Onyeka Anaedozie; Tolu Arowolo; Hope Cassidy-Stewart; CaSaundra Bush; Lucy E Wilson; Alexander J Millman; Noele P Nelson; Lauren Canary; Sherilyn Brinkley; Juhi Moon; Oluwaseun Falade-Nwulia; Mark S Sulkowski; David L Thomas; Michael T Melia
Journal:  J Viral Hepat       Date:  2020-08-05       Impact factor: 3.517

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.